The NBDA is taking on a big challenge. This unprecidented collaboration requires a highly experienced leadership, expertise, skills, and deep knowledge of the biomarker field and the regulatory science. Specifically, the NBDA team brings unprecedented experience and expertise in executive leadership; the development and leadership of large scale scientific initiatives; all aspects of biospecimens and biorepository development; bioinformatics and computational modeling; drug and diagnostics development; advanced technologies; and the specifics of biomarker regulatory science. The management construct is lean by design and will focus on operating at scale through knowledge networks of experts from the biomarker stakeholder communities. The NBDA knowledge networks are a combination of volunteer efforts and directed contract-type work solicited through requests for proposals (RFPs). Work flows involve outside experts and smaller networks to answer “bracketed” questions and/or create new knowledge in biomarker development.
The goal for the management structure is to maximize output and value to stakeholders and minimize costs. Funding for NBDA operations derives from start-up grants from Arizona State University. The NBDA will launch a membership program in 2014 to seek in-kind and financial support from the effected stakeholder communities (private sector, advocacy research foundations, general philanthropy, government, and others). Funding for specific projects will be based on the nature and difficulty of the question and the value proposition of the outcomes.
The start-up management structure for NBDA operations is shown in Figure 1. Dr. Anna Barker serves as the founding President; Dr. Carolyn Compton as the Chief Medical Officer; Dr. George Poste as acting Chief Science Officer; and Dr. Ken Buetow as Director of Bioinformatics and Data Management. The operations of the NBDA is informed by a Steering and Scientific Advisory Committee.